Sloy Dahl & Holst LLC Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Sloy Dahl & Holst LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 7.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,417 shares of the biopharmaceutical company’s stock after buying an additional 521 shares during the quarter. Sloy Dahl & Holst LLC’s holdings in Pfizer were worth $214,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Front Street Capital Management Inc. lifted its stake in Pfizer by 4.3% in the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 215 shares in the last quarter. Castleview Partners LLC lifted its stake in Pfizer by 2.4% in the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 287 shares in the last quarter. United Bank lifted its stake in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares in the last quarter. Compton Capital Management Inc. RI lifted its stake in Pfizer by 0.5% in the 1st quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock worth $3,308,000 after purchasing an additional 300 shares in the last quarter. Finally, GHP Investment Advisors Inc. lifted its stake in Pfizer by 2.4% in the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 307 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.8 %

NYSE:PFE traded down $0.22 during mid-day trading on Wednesday, hitting $25.69. 28,885,313 shares of the stock traded hands, compared to its average volume of 33,467,946. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $145.47 billion, a price-to-earnings ratio of 71.36, a PEG ratio of 1.18 and a beta of 0.61. The firm’s 50 day moving average is $27.23 and its two-hundred day moving average is $28.79. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $41.33.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average price target of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.